Literature DB >> 24060875

Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine.

Beth Williamson1, Kelly E Dooley, Yuan Zhang, David J Back, Andrew Owen.   

Abstract

Rifampin is a potent inducer of cytochrome P450 (CYP) enzymes and transporters. Drug-drug interactions during tuberculosis treatment are common. Induction by rifapentine and rifabutin is understudied. Rifampin and rifabutin significantly induced CYP3A4 (80-fold and 20-fold, respectively) in primary human hepatocytes. The induction was concentration dependent. Rifapentine induced CYP3A4 in hepatocytes from 3 of 6 donors. Data were also generated for ABCB1, ABCC1, ABCC2, organic anion-transporting polypeptide 1B1 (OATP1B1), and OATP1B3. This work serves as a basis for further study of the extent to which rifamycins induce key metabolism and transporter genes.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24060875      PMCID： PMC3837889          DOI： 10.1128/AAC.01124-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Binding of rifampicin by human plasma proteins.

Authors:  G Boman; V A Ringberger
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

2.  The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Authors:  Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

3.  Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells.

Authors:  Yaming Su; Xiaoping Zhang; Patrick J Sinko
Journal:  Mol Pharm       Date:  2004-01-12       Impact factor: 4.939

4.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

Review 5.  Clinical pharmacokinetics of rifampicin.

Authors:  G Acocella
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

6.  Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.

Authors:  Kelly Dooley; Charles Flexner; Judith Hackman; Charles A Peloquin; Eric Nuermberger; Richard E Chaisson; Susan E Dorman
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

7.  Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.

Authors:  Vaishali Dixit; Niresh Hariparsad; Fang Li; Pankaj Desai; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2007-07-16       Impact factor: 3.922

8.  Pharmacogenomics and individualized medicine: translating science into practice.

Authors:  K R Crews; J K Hicks; C-H Pui; M V Relling; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2012-09-05       Impact factor: 6.875

Review 9.  Update on rifampin, rifabutin, and rifapentine drug interactions.

Authors:  Anne M Baciewicz; Cary R Chrisman; Christopher K Finch; Timothy H Self
Journal:  Curr Med Res Opin       Date:  2012-11-30       Impact factor: 2.580

10.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069
View more
  47 in total

1.  Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.

Authors:  Pascale M Abena; Eric H Decloedt; Emmanuel Bottieau; Fatima Suleman; Prisca Adejumo; Nadia A Sam-Agudu; Jean-Jacques Muyembe TamFum; Moussa Seydi; Serge P Eholie; Edward J Mills; Oscar Kallay; Alimuddin Zumla; Jean B Nachega
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Authors:  Kelly E Dooley; Anne F Luetkemeyer; Jeong-Gun Park; Reena Allen; Yoninah Cramer; Stephen Murray; Deborah Sutherland; Francesca Aweeka; Susan L Koletar; Florence Marzan; Jing Bao; Rada Savic; David W Haas
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 3.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

4.  In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.

Authors:  Barbara A Brown-Elliott; Julie V Philley; David E Griffith; Foram Thakkar; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.

Authors:  Annett Kunze; Emmanuel Njumbe Ediage; Lieve Dillen; Mario Monshouwer; Jan Snoeys
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

6.  Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.

Authors:  Helena Rabie; Holly Rawizza; Peter Zuidewind; Jana Winckler; Heather Zar; Annelies Van Rie; Lubbe Wiesner; Helen McIlleron
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

7.  Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Authors:  Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Authors:  Mario Regazzi; Anna Cristina Carvalho; Paola Villani; Alberto Matteelli
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

9.  The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase.

Authors:  Mirjana Lilic; James Chen; Hande Boyaci; Nathaniel Braffman; Elizabeth A Hubin; Jennifer Herrmann; Rolf Müller; Rachel Mooney; Robert Landick; Seth A Darst; Elizabeth A Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

10.  Development of NanoART for HIV Treatment: Minding the Cytochrome P450 (CYP) Enzymes.

Authors:  Narasimha M Midde; Santosh Kumar
Journal:  J Pers Nanomed       Date:  2015-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.